The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Diet Supplement Tied to Hepatitis

Back to News Homepage

Next

43 of 44 Patients Achieved Sustained Virologic Response (SVR)

Key Findings About HCV Genotype 3

April 22, 2014

Print this page

Learn about the clinical data which suggests that interferon-free regimens containing Gilead’s Sovaldi (sofosbuvir) and Bristol-Myers Squibb’s NS5A inhibitor daclatasvir have advantages over currently available regimens for HCV genotype-3 infections.

Regimens Containing Gilead’s Sovaldi Have Major Advantages over Other Therapies for Hepatitis C Virus Genotype-3

Gastroenterologists Would Prescribe Sovaldi plus Daclatasvir plus Ribavirin to 60 Percent of Their Genotype-3 Patients, According to Findings from Decision Resources Group

PR Newswire

BURLINGTON, Mass., April 1, 2014 /PRNewswire/ — Decision Resources Group finds that surveyed gastroenterologists in the United States and Europe agree that the percentage of hepatitis C virus (HCV) genotype-3 infected patients with cirrhosis of the liver achieving a sustained virologic response (SVR) is one of the attributes that most influences their prescribing decisions. Clinical data and interviewed experts indicate that interferon-free regimens containing Gilead’s Sovaldi (sofosbuvir) and Bristol-Myers Squibb’s NS5A inhibitor daclatasvir have convenience and efficacy advantages over currently available regimens for HCV genotype-3 infections. However, competition from other NS5A inhibitors, such as Gilead’s GS-5816, may constrain uptake of daclatasvir.

Continue reading this entire article:
http://www.digitaljournal.com/pr/1825244

1 Comment
Share
Share

Previous

Diet Supplement Tied to Hepatitis

Back to News Homepage

Next

43 of 44 Patients Achieved Sustained Virologic Response (SVR)

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.

  • RW

    I just started the Sovaldi & Ribavarin treatment this past May 6th, 2014. Today (Friday) is my 5th dose and so far no real after effects that are of concern. I am very excited about this. I am one of those people who has been really affected by it. I have been through two (2) Liver transplants. My Spleen was bad and removed. My Gallbladder had to go because my Liver was so bad it had become oversized and difficult to remove. The surgeons had to make an going up my chest to allow for more room. I have also been diagnosed with Chronic Pancreatitis. All a result of Hep-C Virus. I am in a small category of people with Hep C who unfortunately get a great deal of problems/issues as a result.
    I am obviously very dedicated to this treatment and right now see it as the #1 issue in my life. To be free of this dreaded disease will be such a wonderful blessing. Thank God for his gift of science and scientific researchers in all facets. I believe science and God have a place together. Science is a gift from God as are scientists and everything related!